메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Thailand Rings in the New Year at Bangkok's 'Times Square of Asia', Central World

BANGKOK, Jan. 5, 2026 -- Fireworks arced across Bangkok's skyline. Drones lit up the night sky. A sea of people filled the Ratchaprasong district as the city counted down together. At midnight, centralwOrld Bangkok Countdown 2026: The Original – A Tribute to Love transformed the heart of Thailand's capital into a global stage, reinforcing centralwOrld's reputation as the "Times Square of Asia." More than 350,000 people, including international visitors, gathered at the city's most recognisable crossroads to welcome the New Year, turning one of
- 김장윤(JASON KIM) 기자
- 2026-01-05 16:13
Manulife Hong Kong Launches Genesis Centurion Insurance Plan and Prestige Achiever Insurance Plan

[ 메디채널 황정호 기자 ] Two new participating life insurance savings plans designed to empower financial well-being and meet evolving customer needs for flexibility and growth HONG KONG, Jan. 5, 2026 -- Manulife Hong Kong today announced the launch of two new participating life insurance savings plans — Genesis Centurion Insurance Plan and Prestige Achiever Insurance Plan — designed to help customers achieve financial goals with enhanced flexibility and growth potential. Genesis Centurion Insurance Plan is designed to support long-term wealth accumulation and planning, complementing t
- 황정호 기자
- 2026-01-05 13:42
Samsung Unveils World's First 130-Inch Micro RGB TV Featuring Next-Generation Color and Bold New Design

Debuting with advanced picture performance, the new 130-inch Micro RGB TV sets a new standard for ultra-premium displays LAS VEGAS, Jan. 5, 2026 -- Samsung Electronics Co., Ltd. today unveiled the world's first 130-inch Micro RGB TV (R95H model) at CES 2026, marking the debut of its largest Micro RGB display and a bold new design direction for ultra-premium displays. "Micro RGB represents the peak of our picture quality innovation, and the new 130-inch model takes that vision even further," said Hun Lee, Executive Vice President of the Visual Display (V
- 김장윤(JASON KIM) 기자
- 2026-01-05 12:44
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate Phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy. The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients with TGFBI
- 김갑성 기자
- 2026-01-05 12:07
GMA Capital Partners Joins Responsible Investment Association Australasia

SINGAPORE, Jan. 5, 2026 -- GMA Capital Partners has been approved as a member of the Responsible Investment Association Australasia (RIAA), reflecting the firm's continued focus on responsible capital deployment and engagement with established sustainable investment frameworks across the Asia-Pacific region. Headquartered in Singapore, GMA Capital Partners is a principal investment firm focused on long-term investments, structured capital solutions, and cross-border partnerships in real-economy sectors, including infrastructure, energy transition, logistics, and strategic industrial ma
- 황정호 기자
- 2026-01-05 11:00
C&R Research, the 'K-Clinical Hub', Strengthens Partnerships in Indonesia

[ 메디채널 김갑성 기자 ] Accelerating Indonesia Collaboration through Global Clinical Capabilities SEOUL, South Korea, Jan. 5, 2026 -- C&R Research, founded in 1997 as Korea's first full-service Contract Research Organization (CRO), has played a pivotal role in advancing the Korean clinical trial industry and supporting the global expansion of Korean clinical research. With expertise across next-generation modalities, C&R Research has established itself as a key partner in global drug development. Leveraging its global subsidiaries and international network, C&R Research is
- 김갑성 기자
- 2026-01-05 10:00
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026.-ASC30 demonstrated placebo-adjusted weight loss of 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability. No hepatic safety signal was observed. HONG KONG, Jan. 5, 2026 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announc
- 김갑성 기자
- 2026-01-05 08:10
CTA: Despite Tariffs and Economic Headwinds, U.S. Consumer Tech Revenue to Hit $565 Billion in 2026

LAS VEGAS, Jan. 5, 2026 -- As tariff pressures and economic uncertainty impact the business landscape, the Consumer Technology Association (CTA)® today is releasing its U.S. Consumer Technology Industry Forecast showing the industry is projected to reach $565 billion in revenue in 2026, growing 3.7% year over year. The forecast is being unveiled during CTA's Tech Trends to Watch event during Media Days at CES® 2026, where industry leaders are gathering to discuss the latest innovations and assess the year ahead. The outlook underscores the industry's resilience at a piv
- 황정호 기자
- 2026-01-05 07:40
Babies Bliss Establishes a New Standard for Fertility Wellness in Singapore with a Whole-Person, Cycle-Aware Model

Singapore-based Fertility Wellness House positions complementary care as long-term support alongside IVF and assisted fertility treatments SINGAPORE, Jan. 5, 2026 -- Babies Bliss, a leading fertility wellness house in Singapore, is redefining how fertility journeys are supported through a whole-person, cycle-aware fertility wellness model designed to complement medical fertility treatments such as IUI and IVF. As more women and couples navigate prolonged fertility journeys, IVF fatigue, and the emotional strain of repeated treatment cycles, demand is rising for non-medical, supp
- 김갑성 기자
- 2026-01-05 07:00
To See 5,000 Years of China: Visit Hangzhou -- A Global Welcome Awaits

HANGZHOU, China, Jan. 4, 2026 -- Known for centuries as "heaven on earth" in Chinese lore, Hangzhou stands as a living window into China's profound civilization spanning over five millennia. Today, Hangzhou Municipal Bureau of Culture, Radio, Television and Tourism invites global visitors to explore its unparalleled heritage and modern hospitality. To enhance the shopping experience for international guests, Hangzhou has fully implemented and optimized its "Tax Refund for Tourists" (TRT) policy. Eligible overseas tourists can receive a refund on the Value-Ad
- 김장윤(JASON KIM) 기자
- 2026-01-04 15:56

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-11_SUN

2026-01-10_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 11일 03시 20분